Metastatic Castration-Resistant Prostate Cancer Guidelines Pocket Guide - Guideline Central

Metastatic Castration-Resistant Prostate Cancer

American Society of Clinical OncologyPublished: January 20, 2026
  • Pages:22
  • Format:Spiral Bound
  • Dimensions:4.25" x 7.25"
$9.95
  • Key Points
  • Treatment
  • Figures and Algorithms
    • Patients Previously Treated With ADT Alone
    • Patients Previously Treated With ADT and an ARPI
    • Patients Previously Treated with ADT and Docetaxel
    • Patients Previously Treated with ADT, ARPI, and Docetaxel
    • Treatment Options for De Novo or Treatment-Emergent Small Cell Neuroendocrine Carcinoma of the Prostate
  • Tables
    • 10 Most Common Co-occurring Chronic Conditions Among Male Medicare Beneficiaries with Prostate Cancer (N = 1,016,617), 2011
    • Costs
Also Found In

ASCO Guidelines Bundle

$935.95
Related Products
You rely on Guideline Central for transparency

Guideline Central and select third party use “cookies” on this website to enhance the user experience.

This technology helps us gather statistical and analytical information to optimize the relevant content for you.

The user also has the option to opt-out which may have an effect on the browsing experience.